14328-64-4

Basic information

• Product Name: H-D-CHG-OME HCL
• Synonyms: H-D-CHG-OME HCL;D-CYCLOHEXYLGLYCINE METHYL ESTER HYDROCHLORIDE;D-2-CYCLOHEXYLGLYCINE METHYL ESTER HYDROCHLORIDE;(R)-(Amino)(cyclohexyl)ethanoic acid methyl ester hydrochloride;Methyl (2R)-2-amino-2-cyclohexylethanoate hydrochloride;D-CHG-OME HCl;(R)-Methyl 2-aMino-2-cyclohexylacetate hydrochloride;H-D-Chg-OMe hydrochloride
• CAS NO: 14328-64-4
• Molecular Formula: C₉H₁₇NO₂*ClH
• Molecular Weight: 207.7
• Mol File: 14328-64-4.mol
• Article Data: 7

Chemical Properties

• Melting Point: 190-191 °C
• Appearance: /
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• CAS DataBase Reference: H-D-CHG-OME HCL(CAS DataBase Reference)
• NIST Chemistry Reference: H-D-CHG-OME HCL(14328-64-4)
• EPA Substance Registry System: H-D-CHG-OME HCL(14328-64-4)

Safety Data

• Hazard Codes: Xn
• Statements: 22-36/37/38
• Safety Statements: 26
• WGK Germany: 3
• Hazardous Substances Data: 14328-64-4(Hazardous Substances Data)

Usage

General Description

H-D-CHG-OME HCL, also known as hydrochloride of 2-(4-hydroxy-3,5-dimethoxyphenyl)ethyl-dimethylamine, is a chemical compound that belongs to the family of phenethylamine derivatives. It is a hydrochloride salt form of H-D-CHG-OME, which is a research chemical and a potential psychoactive substance. H-D-CHG-OME HCL is often used for research purposes and is not intended for human consumption. It is important to handle this chemical with caution and adhere to proper safety protocols when working with it in laboratory settings.

Upstream product

• 67-56-1 methanol 
• 14328-52-0 (R)-2-amino-2-cyclohexyl acetic acid 
• 61367-40-6 (R)-2-amino-2-cyclohexylacetic acid hydrochloride 
• 14328-51-9 (2S)-amino(cyclohexyl)ethanoic acid 
• 15028-39-4 L-2-phenylglycine methyl ester hydrochloride 

Downstream Products

• 887244-09-9 methyl (2S)-cyclohexyl-{[(4,5-difluoro-2-nitrophenyl)carbonyl]amino}ethanoate 
• 1115354-29-4 (R)-cyclohexyl-(2-nitro-benzoylamino)-acetic acid methyl ester 
• 145618-11-7 (S)-amino(cyclohexyl)acetic acid methyl ester 
• 1000064-08-3 C₁₇H₃₁NO₂ 
• 873581-17-0 (2S)-1-[(2S)-2-[(2S)-2-[[(tert-butoxy)carbonyl](methyl)amino]propanamido]-2-cyclohexylacetyl]pyrrolidine-2-carboxylic acid 
• 1026200-41-8 methyl (2S)-cyclohexyl(isocyanato)acetate 
• 107202-38-0 tert-butyl (S)-(methoxycarbonyl)(cyclohexyl)methylcarbamate 

Relevant articles and documents

Discovery of a novel dipeptidyl boronic acid proteasome inhibitor for the treatment of multiple myeloma and triple-negative breast cancer

A series of novel dipeptidyl boronic acid compounds were designed, synthesized and biologically investigated for the inhibition of the β5 subunit of 20S proteasome and several compounds showed high activities with IC50 values of less than 10 nM. Some of these compounds potently inhibited the multiple myeloma (MM) cancer cell lines with IC50 values of less than 10 nM. It was reported that the inhibition of both β2 and β5 subunits strongly increased the cytotoxicity of proteasome inhibitors in solid tumor cells, so some of the compounds were evaluated for the inhibition of the β2 subunit and the solid tumor triple-negative breast cancer cell line MDA-MB-231. The results showed that three compounds were active for both the β2 subunit and the triple-negative breast cancer cell line MDA-MB-231. The in vivo pharmacokinetic results showed that compound 8t had good biological parameters for both ig and iv administrations. An in vivo pharmacodynamic experiment showed that compound 8t inhibited the β5 subunit in whole blood more greatly than the marketed MLN9708 with the same dose at different time periods. A pathological analysis indicated that the injection of compound 8t in the tumor of a triple-negative breast cancer xenograft mice model led to tumor cell necrosis, nucleus condensation, deep staining, cell fragmentation, dissolution and neutrophil infiltration compared with the control group. The data in hand showed that compound 8t might be an effective candidate for the treatment of both MM and triple-negative breast cancer.

SPIROCYCLIC INDOLINES AS IL-17 MODULATORS

A series of substituted spirocyclic 2-oxoindoline derivatives, and analogues thereof, being potent modulators of human IL-17 activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including inflammatory and autoimmune disorders.

Structure-guided design and optimization of dipeptidyl inhibitors of norovirus 3CL protease. Structure-activity relationships and biochemical, X-ray crystallographic, cell-based, and in vivo studies

Norovirus infection constitutes the primary cause of acute viral gastroenteritis. There are currently no vaccines or norovirus-specific antiviral therapeutics available for the management of norovirus infection. Norovirus 3C-like protease is essential for viral replication, consequently, inhibition of this enzyme is a fruitful avenue of investigation that may lead to the emergence of antinorovirus therapeutics. We describe herein the optimization of dipeptidyl inhibitors of norovirus 3C-like protease using iterative SAR, X-ray crystallographic, and enzyme and cell-based studies. We also demonstrate herein in vivo efficacy of an inhibitor using the murine model of norovirus infection.